Table of Contents:
  • Why conduct phase I-II trials?
  • The phase I-II paradigm
  • Establishing priors
  • Efficacy : toxicity trade-off-based designs
  • Designs with late-onset outcomes
  • Utility-based designs
  • Personalized dose finding
  • Combination trials
  • Optimizing molecularly targeted agents
  • Optimizing doses in two cycles
  • Optimizing dose and schedule
  • Dealing with dropouts
  • Optimizing intra-arterial tPA
  • Optimizing sedative dose in preterm infants.